Kailera Therapeutics raised $400M in a series A funding round co-led by Atlas Venture, Bain Capital Life Sciences, and RTW Investments to advance its portfolio of obesity drugs.

Oct 01, 2024•about 1 year ago

Amount Raised

$400 Million

Round Type

series a

WalthamresearchBiotechnologyHealth Care

Investors

Lyra CapitalRtw InvestmentsBain Capital Life SciencesAtlas Venture

Description

Kailera Therapeutics has launched with a significant backing of $400 million in series A funding to support its entry into the obesity market with acquired assets from China. The funding will help advance its innovative therapies that aim to improve quality of life and health for individuals struggling with obesity.

Company Information

Company

Kailera Therapeutics

Location

890 Winter Street

Waltham, Massachusetts, United States

About

Kailera Therapeutics (Kailera) is developing a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity. Kailera’s most advanced program, KAI-9531 (being developed in China as HRS9531), is an injectable GLP-1/GIP receptor dual agonist that demonstrated positive clinical trial results in obesity in China. The Company is also advancing a diversified pipeline leveraging several mechanisms and routes of delivery. Kailera’s mission is to develop next-generation weight management therapies that give people the power to transform their lives and elevate their overall health.

Related People

5 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends